-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 19, 2021 //---Recently, the international cooperation between Great Ormond Street Hospital, UCL GOS Institute for Child Health and Harvard Medical School has shown that the benefits of gene therapy can be eliminated by the body in transplanted blood stem cells It won’t be seen until decades later.
The research team monitored five patients who successfully cured SCID-X1 through GOSH gene therapy.
From 3 to 18 years, the patient’s blood is analyzed regularly to detect which cell types and biomarker chemicals are present in the blood.
The results show that even if the patient has eliminated the stem cells transplanted as part of the gene therapy vector, the corrected T cells are still being formed.
From 3 to 18 years, the patient’s blood is analyzed regularly to detect which cell types and biomarker chemicals are present in the blood.
The results show that even if the patient has eliminated the stem cells transplanted as part of the gene therapy vector, the corrected T cells are still being formed.
(Image source: www.
pixabay.
com)
pixabay.
com)
The working principle of gene therapy is to first remove some hematopoietic stem cells from the patient.
These stem cells produce various types of blood and immune cells.
Next, in the laboratory, a viral vector is used to deliver a new copy of the defective gene into the DNA of the patient's cells.
These corrected stem cells are then returned to the patient in a so-called "autologous transplantation" method, and then continue to produce healthy immune cells that can fight infection.
These stem cells produce various types of blood and immune cells.
Next, in the laboratory, a viral vector is used to deliver a new copy of the defective gene into the DNA of the patient's cells.
These corrected stem cells are then returned to the patient in a so-called "autologous transplantation" method, and then continue to produce healthy immune cells that can fight infection.
In SCID-X1 gene therapy, the corrected stem cells are finally eliminated by the human body, but the patient can still be cured.
The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
(Bioon.
com)
(Bioon.
com)
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
html">Cellular benefits of gene therapy seen decades after treatment
html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
(Image source: www.
pixabay.
com)
pixabay.
com)
The working principle of gene therapy is to first remove some hematopoietic stem cells from the patient.
These stem cells produce various types of blood and immune cells.
Next, in the laboratory, a viral vector is used to deliver a new copy of the defective gene into the DNA of the patient's cells.
These corrected stem cells are then returned to the patient in a so-called "autologous transplantation" method, and then continue to produce healthy immune cells that can fight infection.
These stem cells produce various types of blood and immune cells.
Next, in the laboratory, a viral vector is used to deliver a new copy of the defective gene into the DNA of the patient's cells.
These corrected stem cells are then returned to the patient in a so-called "autologous transplantation" method, and then continue to produce healthy immune cells that can fight infection.
In SCID-X1 gene therapy, the corrected stem cells are finally eliminated by the human body, but the patient can still be cured.
The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
(Bioon.
com)
(Bioon.
com)
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
html">Cellular benefits of gene therapy seen decades after treatment
html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
In SCID-X1 gene therapy, the corrected stem cells are finally eliminated by the human body, but the patient can still be cured.
The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
(Bioon.
com)
(Bioon.
com)
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
html">Cellular benefits of gene therapy seen decades after treatment
html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
(Bioon.
com)
(Bioon.
com)
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
html">Cellular benefits of gene therapy seen decades after treatment
html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
(Bioon.
com)
(Bioon.
com)
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
html">Cellular benefits of gene therapy seen decades after treatment
html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
html">Cellular benefits of gene therapy seen decades after treatment
Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades. html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
html">Cellular benefits of gene therapy seen decades after treatment
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
DOI: 10.
1038/s41467-021-21834-9
Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
DOI: 10.
1038/s41467-021-21834-9
Original source: Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature CommunicationsDOI: 10.
1038/s41467-021-21834-9
